Role of Uralyt-U in Patients With Hyperuricemia

• Status: Recruiting
• Trial end date: 2020-10-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to provide a more direct and objective basis for the widespread use of potassium sodium hydrogen citrate granules in the treatment of uric acid stones.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ai Peng
• Treatments: Citric Acid; Febuxostat

Criteria

Inclusion Criteria:

• 18-70 years old, male, outpatient or inpatient;

• Acidic urinary stones

• Serum uric acid value ≥480 µmol / L;

• Other concomitant diseases (such as hypertension, hyperlipidemia, diabetes, etc.) are in a stable condition, and the dosage of other diseases is not changed during the test.

• eGFR≥30ml / min;

Exclusion Criteria:

• Pregnant or lactating women;

• Patients with acute or chronic renal failure (eGFR <30ml / min);

• Patients with severe liver dysfunction (ALT, AST≥70 IU);

• In patients with uncontrolled hypertension, systolic blood pressure ≥160 and / or diastolic blood pressure ≥110mmHg;

• In uncontrolled diabetic patients, fasting blood glucose is> 10mmol / L, and / or glycated hemoglobin is ≥9%;

• Patients that are taking atorvastatin, losartan, amlodipine, fenofibrate, pyrazinamide, tincture diuretics, thiazide diuretics, glucocorticoids, immunosuppressive agents and other drugs that affect uric acid excretion Drugs, those taking aspirin at a dose of> 325mg / day;

• Cancer patients